LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Drug Discovery Targeting Drug-Resistant Bacteria
- 1st Edition - May 15, 2020
- Editors: Prashant Kesharwani, Sidharth Chopra, Arunava Dasgupta
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 8 4 8 0 - 6
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 8 4 8 1 - 3
Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microb… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteDrug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included.
Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful.
- Written by scientists with extensive industrial experience in drug discovery
- Provides a balanced view of the field, including its challenges and future directions
- Includes a special chapter on the identification and development of drugs against pathogens which exhibit the potential to be used as weapons of war
1. What are drugs and why are they required?2. Drugs against gram-negative bacteria3. Drugs targeting gram-positive bacteria4. Drug repurposing against bacteria5. Drugs against M. tuberculosis6. Drugs against TB and Bioweapons7. New approaches to drug discovery: Peptides/quorum sensing/virulence8. New strategies and targets for antibacterial discovery9. Targeting efflux pumps for AMR10. Discovering antibiotics from Phages11. Drugs against non-tuberculous mycobacteria
- No. of pages: 432
- Language: English
- Edition: 1
- Published: May 15, 2020
- Imprint: Academic Press
- Paperback ISBN: 9780128184806
- eBook ISBN: 9780128184813
PK
Prashant Kesharwani
Dr. Prashant Kesharwani is working as an assistant professor of pharmaceutics at the School of Pharmaceutical Education and Research, Jamia Hamdard University, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 20 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also a receipt of several internationally acclaimed awards such as the most prestigious “Ramanujan Fellowship Award” from the Science and Engineering Research Board, Government of India. He actively participates in outreach and scientific dissemination for the service of the wider community.
Affiliations and expertise
Assistant Professor, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, IndiaSC
Sidharth Chopra
Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens.
Affiliations and expertise
Senior Scientist, Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, IndiaAD
Arunava Dasgupta
Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.
Affiliations and expertise
Senior Scientist, Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, IndiaRead Drug Discovery Targeting Drug-Resistant Bacteria on ScienceDirect